ClinicalTrials.gov record
Active, not recruiting Phase 2Phase 3 Interventional

A Study of AL102 in Patients With Progressing Desmoid Tumors

ClinicalTrials.gov ID: NCT04871282

Public ClinicalTrials.gov record NCT04871282. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 19, 2026, 7:52 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

RINGSIDE: A Phase 2/3, Randomized, Multicenter Study to Evaluate AL102 in Patients With Progressing Desmoid Tumors

Study identification

NCT ID
NCT04871282
Recruitment status
Active, not recruiting
Study type
Interventional
Phase
Phase 2, Phase 3
Lead sponsor
Immunome, Inc.
Industry
Enrollment
198 participants

Conditions and interventions

Interventions

  • AL102 Drug
  • Placebo Other

Drug · Other

Eligibility (public fields only)

Age range
12 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Mar 29, 2021
Primary completion
Dec 2, 2025
Completion
Sep 30, 2026
Last update posted
Feb 4, 2026

2021 – 2026

United States locations

U.S. sites
23
U.S. states
14
U.S. cities
20
Facility City State ZIP Site status
Mayo Clinic Pheonix Arizona 85054
City of Hope Duarte California 91010
Sarcoma Oncology Research Center Santa Monica California 90403
University of California at Los Angeles Hematology/Oncology Santa Monica California 90404
Stanford University Medical Center Stanford California 94305
Mayo Clinic Jacksonville Florida 32224
NorthShore University Health System Evanston Illinois 60201
Massachusetts General Hospital Boston Massachusetts 02214
University of Michigan Ann Arbor Michigan 48109
Jefferson City Medical Group Jefferson City Missouri 65109
Washington University St Louis Missouri 63110
Columbia University Irving Medical Center New York New York 10032
Memorial Sloan Kettering Cancer Center New York New York 10065
Levine Cancer Institute Charlotte North Carolina 28204
Cleveland Clinic Cleveland Ohio 44195
Ohio State University Wexner Medical Center Columbus Ohio 43210
Oregon Health & Science University Portland Oregon 97239
Jefferson University Hospital Philadelphia Pennsylvania 19107
Fox Chase Cancer Center Philadelphia Pennsylvania 19111
University of Pittsburgh Medical Center, Hillman Cancer Center Pittsburgh Pennsylvania 15232
UTSW Simmons Cancer Center Dallas Texas 75235
MD Anderson Cancer Center Houston Texas 77005
Fred Hutchinson Cancer Center Seattle Washington 98109

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 30 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT04871282, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Feb 4, 2026 · Synced May 19, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT04871282 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →